Ledford, Heidi

Heidi Ledford is a science journalist who covers biology and the social sciences for Nature. She has a PhD from the University of California, Berkeley and has written for The Oregonian, edited for the Berkeley Science Review, and freelanced for various publications. Her interests include medicine, CRISPR, cancer, plants, GM organisms, translational and clinical research, patents and COVID-19 drugs.

Biography:  https://www.nature.com/nature/editors

86%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

50%

Examples:

  • Two studies suggest that the risk of lung cancer decreases in octogenarians.

Deceptions

55%

Examples:

  • The results, posted as preprints on the bioRxiv server, highlight specific genes that could contribute to the declining risk and reveal a surprising link between them and iron metabolism. The studies have not yet been peer reviewed.

Recent Articles

Unraveling the Mystery of Ageing and Cancer: Insights from Recent Research

Unraveling the Mystery of Ageing and Cancer: Insights from Recent Research

Broke On: Friday, 05 July 2024 Cancer burden rises, particularly in low-income countries, but advancements in treatment and lifestyle modifications have led to decreased deaths and improved survival rates. Despite this progress, cancer phobia persists due to fear of side effects and prominent cases. Recent studies suggest aging may make cancer less conducive to growth through altered iron metabolism.
Promising Breakthrough in Glioblastoma Treatment with CAR T Cells: Early Hints of Progress from Two Preliminary Studies

Promising Breakthrough in Glioblastoma Treatment with CAR T Cells: Early Hints of Progress from Two Preliminary Studies

Broke On: Thursday, 14 March 2024 Two studies show promise of CAR T cells against glioblastoma, a deadly brain cancer. The engineered immune cells target two proteins found in the tumor and may extend survival.